Skip to main content

Table 1 Clinical trials included in the analysis and fitted parameters for each trial. The study sites are shown in order of increasing transmission intensity, as estimated by the hidden semi-Markov model analysis. Prior EIRs are estimated from the Malaria Atlas Project slide prevalence for each location in the year of the trial [28, 29]

From: The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data

Site and reference Country, year PCR correction: molecular markers N (AL/AS-AQ) AS-AQ manufacturer (formulation), target AQ dose* Days of prophylaxis: posterior median (95% CI) EIR FOI† Prevalence of pfmdr1 86Y, % (references) Prevalence of pfcrt 76T, % (references)
      AL AS-AQ Prior mean Posterior median (95% CI)    
Fougamou [23] Gabon, 2007–2008 msp1,msp2,glurp 68/68 Sanofi-Aventis (FDC Coarsucam) 30 mg/kg 11.6 (6.0–16.8) 13.1 (7.6–18.6) 0.6 2.3 (1.1–4.2) 0.5 79.5 [30] 97.9 [31]
Ndola [23] Zambia, 2007–2009 msp1,msp2,glurp 69/64 Sanofi-Aventis (FDC Coarsucam) 30 mg/kg 10.8 (6.0–14.8) 16.1 (9.7–25.0) 1.2 4.8 (2.4–8.4) 1.0 No matching survey 20.8 [32]
Pweto [33] Democratic Republic of Congo 2008-2009 msp1,msp2,glurp 126/129 Sanofi-Aventis (AS-AQ Winthrop FDC) 30 mg/kg 11.3 (7.8–14.4) 17.9 (12.1–25.6) 50.0 9.3 (6.2–13.7) 2.0 No matching survey No matching survey
Pamol [23] Nigeria, 2007–2008 msp1,msp2,glurp 164/159 Sanofi-Aventis (FDC Coarsucam) 30 mg/kg 17.9 (12.3–22.5) 15.4 (10.3–21.7) 22.6 9.5 (4.7–21.6) 2.2 61.8 [34,35,36] 90.1 [37]
Bobo Dioulasso (unpublished‡) Burkina Faso, 2010–2012 msp1,msp2 373/372 Sanofi-Aventis (FDC Coarsucam) 30 mg/kg 12.5 (10.6–14.4) 16.9 (14.0–19.9) 21.5 17.4 (13.3–23.1) 5.9 18.0 [38, 39] 28.5 [38,39,40,41,42]
Gourcy (unpublished‡) Burkina Faso, 2010–2012 msp1,msp2 112/129 Sanofi-Aventis (FDC Coarsucam) 30 mg/kg 8.7 (6.2–10.9) 17.8 (13.7–22.1) 22.9 23.3 (15.9–33.7) 6.5 18.0 [38, 39] 24.8 [39, 41]
Kisumu (unpublished‡) Kenya, 2005 msp1,msp2 179/178 Sanofi and Hoechst Marion Roussel (Loose NFDC) 30 mg/kg 18.6 (15.8–21.2) 14.2 (10.9–17.6) 6.9 26.5 (18.1–39.6) 5.7 66.6 [43,44,45,46] 90.3 [44, 46, 47]
Nimba [48] Liberia, 2008–2009 msp1,msp2,glurp 127/141 Sanofi-Aventis (AS-AQ Winthrop FDC) 30 mg/kg 17.9 (15.1–20.6) 11.6 (8.8–14.3) 18.3 32.4 (26.1–40.0) 8.0 69.4 [49] 93.5 [49]
Sikasso [50] Mali 2005-2007 msp1,msp2,CA1 236/233 Sanofi-Aventis (Coblistered NFDC. Arsucam) 30 mg/kg 10.2 (9.0–11.6) 18.7 (16.1–21.5) 25.2 37.2 (29.5–46.9) 11.3 35.5 [51] 70.2 [32, 51,52,53,54]
Tororo [55] Uganda, 2009–2010 msp1,msp2,glurp 190/190 Sanofi (AS-AQ Winthrop FDC) 30 mg/kg 13.3 (11.8–14.6) 13.4 (11.7–15.1) 23.3 84.2 (72.9–96.9) 16.9 63.9 [56,57,58] 99.6 [56, 58]
Nanoro [23] Burkina Faso, 2007–2008 msp1,msp2,glurp 257/273 Sanofi-Aventis (FDC Coarsucam) 30 mg/kg 10.1 (9.2–11.1) 17.0 (15.0–19.2) 52.2 91.9 (76.2–111.1) 18.9 31.6 [38, 59] 67.0 [32, 38, 42, 59]
Tororo [60] Uganda, 2005 msp1,msp2 189/195 AQ: Parke-David, Pfizer, AS: Sanofi-Aventis (Loose NFDC) 25 mg/kg 12.4 (11.1–13.8) 10.2 (8.9–11.6) 64.6 117.1 (98.4–139.8) 23.3 79.4 [56, 61] 96.2 [62, 63]
  1. *FDC fixed-dose combination, NFDC non-fixed-dose combination. AS-AQ FDC was from Sanofi. For AL, all trials used the Novartis fixed-dose combination and the same dose regimen
  2. †FOI force of infection, estimated mean incidence of patent blood-stage infection in this trial population, given the age distribution and fitted EIR
  3. ‡ Unpublished study references: Bobo Dioulasso, Gourcy: Nikiema F, Zongo I, Some F, Ouedraogo J. Evolution of therapeutic efficacies of artemisinin-based combination therapies (ASAQ and AL) for treatment of uncomplicated falciparum malaria in Burkina Faso during five years of adoption as first-line treatments, unpublished. and Kisumu: Juma EA. Efficacy of co-administered amodiaquine plus artesunate and artemether/lumefantrine for the treatment of uncomplicated falciparum malaria in children less than five years in different epidemiological settings in Kenya, unpublished.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us